BofA/Merrill Lynch Downgrades ResMed (RMD) to Neutral
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $224.99 --0%
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 17
Rating Summary:
12 Buy, 12 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 5 | Down: 4 | New: 17
Join SI Premium – FREE
BofA/Merrill Lynch downgraded ResMed (NYSE: RMD) from Buy to Neutral.
Analyst William Dunlop says FY 2018 should be "great" but does not believes the current trajectory is setting to make it so. The analyst comments that market share gains appear difficult.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $77.48 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Downgrades Equity LifeStyle Properties (ELS) to Neutral
- Evercore ISI Upgrades The Macerich Company (MAC) to Outperform, 'improving balance sheet and accelerating FFO growth'
- Texas Capital Securities Downgrades Universal Technical Institute (UTI) to Hold
Create E-mail Alert Related Categories
Analyst Comments, DowngradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
